FTSE 100 drops 1.26% as political turmoil in Europe hits
In the current markets, the pound fell 0.49% against the US dollar at 1.1472..
Company
Allergy Therapeutics PLC
LON:AGY
Allergy Therapeutics PLC is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The company sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
298 stories · page 9 of 15
VR Education zips higher as another director puts his money where his mouth is
Some of the main news-driven risers and fallers on Monday afternoon...
Archive
Proactive news snapshot: Proactive news snapshot: Allergy Therapeutics, Netscientific. Kibo Mining …
A glance at some of the day's highlights from the Proactive Investors newswire
Allergy Therapeutics readies grass pollen treatment for Phase III trial after “extremely positive” mid-stage results
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
Investments and investor services
FTSE 100 propelled to new record close as pound weakens and Dow Jones breaches 25,000
FTSE 100 reached a new record close on Monday after achieving it last time on Thursday
Archive
Proactive news snapshot: HemoGenyx Pharmaceuticals, Harvest Minerals, Touchstone Exploration …
A glance at some of the day's highlights from the Proactive Investors newswire
MTI Wireless shares fall as it reports decrease in revenues and profit
A look at some of the top risers and fallers in London on Monday
Allergy Therapeutics highlights benefits of adjuvant technology in new paper
The study highlighted Allergy’s microcrystalline tyrosine (MCT) was a suitable and flexible alternative to aluminium hydroxide
FTSE 100 closes in red as there is little around to spark investor interest
FTSE 250 fared better though closing ahead by around 15 points at 20,800.
Archive
Proactive news snapshot: Instem, Harvest Minerals, MySQUAR …
A glance at some of the day's highlights from the Proactive Investors newswire
Volvere shares gain as it estimates record 2017 revenues
A look at some of the biggest risers and fallers in London on Wednesday
Allergy Therapeutics grows market share ahead of key trial results
Interim revenues at the hay fever vaccine specialist rose by 4% to £42.2mln
Investments and investor services
FTSE 100 closes in positive territory despite Trump trade war fears
Around 3.50pm, the FTSE 100 index was up 13 points at 7,160
Archive
Proactive news snapshot: Mosman Oil And Gas, Midatech Pharma, Thor Mining …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Defenx dented after downbeat trading update; is exploring funding options
Defenx is not the first software company to invoice customers only to see the orders delayed
Allergy Therapeutics teams up with German manufacturer to scale up production of peanut allergy vaccine
Chief executive Manuel Llobet said: "The disruption to patients' social and family life as a result of food allergies is significant, and we are committed to addressing these current unmet needs"
Investments and investor services
FTSE 100 closes firmly lower on chilly Wednesday with ITV the big switch-off
The Footsie may have mainly traded sideways throughout the day but there have been some notable movements among blue-chips.
Archive
Proactive news snapshot: Oracle Power, Anglo Asian Mining, 88 Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
Allergy Therapeutics' grass pollen study running ahead of schedule
The Phase II study of its PQ Grass immunotherapy, an aluminium-free, ultra-short course hay fever treatment, is designed to evaluate dose response and safety
Investments and investor services
FTSE 100 heats up as defensives are given the cold shoulder
The index of blue-chip shares eased off a little in the final half-hour